Hong Kong's Sisram Medical H1 profit falls on China injectables investments

Sisram Medical

19/08/2026 13:19

Overview
Hong Kong medical aesthetics firm's H1 revenue rose 3.6% yr/yr to $171.4 mln
Net profit and adjusted net profit declined, weighed by China investments and North America weakness
Injectables revenue surged 54% yr/yr, becoming the company’s second growth pillar

Outlook
Sisram to focus on profitability recovery and cash conversion in second half of 2026
Company to accelerate DAXXIFY rollout and expand Beijing facility production in China
Sisram aims to restore North America growth by launching new devices and improving efficiency

Result Drivers
INJECTABLES EXPANSION - Rapid growth in injectables, led by DAXXIFY rollout in China, drove revenue increase and consolidated injectables as second growth pillar
APAC AND INTERNATIONAL SALES - Strong performance in APAC, Europe, and Middle East/Africa offset North America decline, supporting overall growth
CHINA INVESTMENTS AND NORTH AMERICA WEAKNESS - Profitability pressured by investment in China injectables and softer North America results

Company press release: ID:nPn2M3HCLa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$171.40 mln
 

Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Sisram Medical Ltd is HK$4.50, about 107.9% above its August 19 closing price of HK$2.17
The stock recently traded at 4 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
Aug 19 - Sino Biopharmaceutical H1 revenue up 10.6% on innovative drug sales
Aug 17 - China Medical System H1 revenue rises on jump in sales of innovative and exclusive products
Aug 18 - Giant Biogene's profit drops on higher distribution expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)